These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 13947380)

  • 1. [On the effects of I-DOPA on motor disorders in Parkinson's syndrome. An electromyographic study].
    GERSTENBRAND G; PATEISKY K
    Wien Z Nervenheilkd Grenzgeb; 1962; 20():90-100. PubMed ID: 13947380
    [No Abstract]   [Full Text] [Related]  

  • 2. [The L-dihydroxyphenylalanine (L-DOPA) effect in Parkinson's syndrome in man: On the pathogenesis and treatment of Parkinson akinesis].
    BIRKMAYER W; HORNYKIEWICZ O
    Arch Psychiatr Nervenkr Z Gesamte Neurol Psychiatr; 1962; 203():560-74. PubMed ID: 13971142
    [No Abstract]   [Full Text] [Related]  

  • 3. Dopamine metabolism in Parkinson's disease.
    GREER M; WILLIAMS CM
    Neurology; 1963 Jan; 13():73-6. PubMed ID: 13950225
    [No Abstract]   [Full Text] [Related]  

  • 4. L-dopa in Parkinson's syndrome.
    Poskanzer DC
    N Engl J Med; 1969 Feb; 280(7):382-3. PubMed ID: 5764823
    [No Abstract]   [Full Text] [Related]  

  • 5. [The L-3,4-dioxyphenylalanine (DOPA)-effect in Parkinson-akinesia].
    BIRKMAYER W; HORNYKIEWICZ O
    Wien Klin Wochenschr; 1961 Nov; 73():787-8. PubMed ID: 13869404
    [No Abstract]   [Full Text] [Related]  

  • 6. Dihydroxyphenylalanine in extrapyramidal disease.
    FRIEDHOFF AJ; HEKIMIAN L; ALPERT M; TOBACH E
    JAMA; 1963 Apr; 184():285-6. PubMed ID: 13959772
    [No Abstract]   [Full Text] [Related]  

  • 7. Paralysis agitans and L-dopa drug therapy.
    Redden M
    Nurs Times; 1972 Mar; 68(9):262-5. PubMed ID: 5018121
    [No Abstract]   [Full Text] [Related]  

  • 8. Dihydroxyphenylalanine (DOPA) in plasma during dopa treatment of patients with Parkinson's disease.
    Tyce GM; Muenter MD; Owen CA
    Mayo Clin Proc; 1970 Jun; 45(6):438-43. PubMed ID: 5425103
    [No Abstract]   [Full Text] [Related]  

  • 9. [Cardiovascular effects of L-dopa and decarboxylase inhibitor on patients with Parkinson's disease].
    Desjacques P; Moret P; Gauthier G
    Schweiz Med Wochenschr; 1973 Dec; 103(50):1783-5. PubMed ID: 4129257
    [No Abstract]   [Full Text] [Related]  

  • 10. [Effect of L-DOPA on the akinesis in Parkinson's syndrome].
    Bischoff A
    Schweiz Med Wochenschr; 1967 Sep; 97(35):1158-9. PubMed ID: 5593650
    [No Abstract]   [Full Text] [Related]  

  • 11. [Parkinson "plus"].
    Fabre N; Brefel-Courbon C; Rascol O
    Rev Prat; 1997 May; 47(10):1077-82. PubMed ID: 9208670
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Treatment of Parkinson's syndrome with L-dopa and its methylated derivatives: 3-OMD and 4-OMD associated with a decarboxylase inhibitor. Clinical and biochemical study].
    Tissot R; Bartholini G; Constantinidis J; Eisenring JJ; Geissbühler F; Yanniotis G; de Ajuriaguerra J
    Schweiz Med Wochenschr; 1973 Oct; 103(42):1466-74. PubMed ID: 4750149
    [No Abstract]   [Full Text] [Related]  

  • 13. [Treatment of Parkinson's disease with L-dopa and with a combination of L-dopa and dopa-decarboxylase inhibitor].
    Agnoli A; Casacchia M; Reitano M; Ruggieri S; Barba C; Zamponi A
    Minerva Med; 1972 Dec; 63(89):4853-61. PubMed ID: 4566743
    [No Abstract]   [Full Text] [Related]  

  • 14. [L-dopa therapy of Parkinson's syndrome. Comparison of pure L-dopa and the combination preparation L-dopa and decarboxylase inhibitor].
    Görlich J; Markus E
    Dtsch Med Wochenschr; 1972 Aug; 97(34):1246-8. PubMed ID: 5048316
    [No Abstract]   [Full Text] [Related]  

  • 15. A double blind study of 1-dopa treatment in Parkinson's disease.
    Rinne UK; Sonninen V
    Eur Neurol; 1968; 1(3):180-91. PubMed ID: 4880674
    [No Abstract]   [Full Text] [Related]  

  • 16. Autonomic dysfunction in Parkinson's syndrome.
    Appenzeller O; Goss J
    Trans Am Neurol Assoc; 1970; 95():200-3. PubMed ID: 5514369
    [No Abstract]   [Full Text] [Related]  

  • 17. L-dopa in parkinson's syndrome.
    Cotzias GC; Papavasiliou PS; Gellene R
    N Engl J Med; 1969 Jul; 281(5):272. PubMed ID: 5791298
    [No Abstract]   [Full Text] [Related]  

  • 18. Parkinson's disease: L-dopa treatment and handwriting area.
    Knopp W; Paulson G; Allen JN; Smeltzer D; Brown FD; Kose W
    Curr Ther Res Clin Exp; 1970 Mar; 12(3):115-25. PubMed ID: 4985489
    [No Abstract]   [Full Text] [Related]  

  • 19. [Parkinson's syndrome. 7. Experiences with L-dopa-treatment].
    Svanborg A
    Lakartidningen; 1970 Oct; 67(42):4827-31. PubMed ID: 5478708
    [No Abstract]   [Full Text] [Related]  

  • 20. L-dopa therapy of Parkinson's disease: plasma L-dopa concentration, therapeutic response, and side effects.
    Muenter MD; Tyce GM
    Mayo Clin Proc; 1971 Apr; 46(4):231-9. PubMed ID: 5573818
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.